

Technical Data Sheet

PE Conjugated Human CD30/TNFRSF8 Protein (C-His)

Catalog Number: 804701, 804702

Size: 25 ug, 100 ug

Target Name: TNFRSF8, CD30, Ki-1

Regulatory Status: RUO

Product Details

Application: FC

Format: Liquid, PE

Expression Host: CHO

Species: Human

Sources: Recombinant Human CD30 protein (phe19-Lys379) with C-terminus His tag is expressed in CHO cells and conjugated to PE.

Accession Number: P28908

Molecular Weight: The protein has a predicted molecular weight of 40 kDa. Under DTT-reducing conditions, it migrates at approximately 50-80 kDa on SDS-PAGE prior to conjugation.

Affinity Tag: C-His

Formulation: 1xPBS buffer, pH7.4, 0.09% NaN₃ with a carrier protein

Endotoxin level: Not tested

Protein Concentration: 25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration.

Storage and Handling: Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months.

Background Information

CD30, also known as TNFRSF8, is a 120 kDa type I transmembrane glycoprotein from the TNF receptor superfamily. It is expressed on activated T, B, and NK cells, but not resting cells. CD30 is cleaved by metalloproteinases into a soluble form and is highly expressed in classical Hodgkin lymphoma and anaplastic large cell lymphoma. It interacts with proteins like TRAF1, TRAF2, and TRAF5, activating NF-κB signaling. This signaling regulates the proliferative potential of autoreactive CD8 T cells and protects against autoimmunity. CD30 is a therapeutic target in lymphoma immunotherapy and plays a role in autoimmune diseases like rheumatoid arthritis.